Phaseline

Companies › InSilico Medicine Hong Kong

InSilico Medicine Hong Kong: clinical trials, targets and expected readouts

6 active drug programs in 7 registered trials: 4 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Immunology, Respiratory, Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rentosertib (INS018_055)
ALK5 inhibitor
–Phase 3Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)Oct 2029
ISM5411 (Garutadustat)
PHF8 inhibitor
PHF8Phase 2Ulcerative ColitisAug 2027
ISM8207–Phase 1Advanced Solid TumorsNov 2026
ISM8969–Phase 1Healthy Subjects (HS)Jan 2027
ISM6331–Phase 1Malignant MesotheliomaAug 2027
ISM3412–Phase 1Locally Advanced/Metastatic Solid TumorsMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05975983Rentosertib (INS018_055)Phase 2Idiopathic Pulmonary Fibrosis (IPF)RespiratoryFeb 2026
NCT06445517ISM8207Phase 1Advanced Solid TumorsOncologyNov 2026
NCT07581431ISM8969Phase 1Healthy Subjects (HS)CardiovascularJan 2027
NCT07265570ISM5411 (Garutadustat)Phase 2Ulcerative ColitisImmunologyAug 2027
NCT06566079ISM6331Phase 1Malignant MesotheliomaOncologyAug 2027
NCT06414460ISM3412Phase 1Locally Advanced/Metastatic Solid TumorsOncologyMar 2028
NCT07687459Rentosertib (INS018_055)Phase 3Idiopathic Pulmonary FibrosisRespiratoryOct 2029

Targets

PHF8 (1)

Companies with the same targets

–

Companies built like this

Jemincare Jacobio Pharmaceuticals DualityBio Deciphera Pharmaceuticals Chengdu New Radiomedicine Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.